Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List

Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy

Conditions: Malignant Pleural Mesothelioma
Start Date: December 1, 2010
Phase: Phase II
Status: Recruiting
NCT ID: NCT01265433
Study Type: Interventional
Intervention: Biological: WT-1-vaccine Montanide + GM-CSF|Biological: Montanide adjuvant + GM-CSF
Study Design: Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment
Results: No Results Available
Sponsors: Memorial Sloan-Kettering Cancer Center|Department of Defense
Ages: Adult|Senior
Enrollment: 78
Funded By: Other|U.S. Fed
First Received: December 21, 2010
End Date: December 1, 2014
Last Updated: December 22, 2010
Last Verified: December 1, 2010

Mesothelioma
Lawsuit Evaluation

First Name
Last Name
Phone Number
Email
Zip Code
Details:
Please Include Diagnosis Date
Type The Number Below: